Risk Adjusted Net Present Value: What is the current valuation of BioNTech's BNT-311/312

Retrieved on: 2023-12-05 16:11:48

Tags for this article:

Click the tags to see associated articles and topics

Risk Adjusted Net Present Value: What is the current valuation of BioNTech's BNT-311/312. View article details on hiswai:

Excerpt

BNT-311/312 is a monoclonal antibody commercialized by BioNTech, with a leading Phase II program in Head And Neck Cancer.

Article found on: www.pharmaceutical-technology.com